Table 1.

Clinicopathologic data for HPV+ and HPV− patients included in this study.

Clinical parameter	Patient demographics
	HPV+ patients				HPV− patients
	TCIA training (ST, n = 100)	TCIA validation (SV, n = 237)	CCF validation (SCCF, n = 120)	p-value	TCIA training (ST, n = 80)	TCIA validation (SV, n = 45)	p-value
Age	60.4 ± 9.07	58.3 ± 9.43	59.45 ± 9.52	0.11	65.54 ± 10.39	64.87 ± 9.63	0.63
Gender
Male	82 (82%)	197 (83.1%)	108 (90%)	0.16	58 (72.5%)	31 (68.9%)	0.82
Female	18 (18%)	40 (16.9%)	12 (10%)		22 (27.5%)	14 (31.1%)
Smoking history
Non-smoker	41 (41%)	83 (35%)	47 (35%)		5 (6.3%)	7 (15.6%)	0.18
Ex-smoker	39 (39%)	95 (40.1%)	51 (40.1%)	0.59	30 (37.5%)	18 (40%)
Current	20 (20%)	59 (24.9%)	22 (24.9%)		45 (56.2%)	20 (44.4%)
Drinking history
Non-/light drinker	82 (82%)	191 (80.6%)	102 (85%)	0.39	39 (48.8%)	22 (48.9%)	0.70
Ex-drinker	6 (6%)	12 (5.1%)	9 (7.5%)		9 (11.2%)	9 (20%)
Heavy drinker	12 (12%)	34 (14.3%)	9 (7.5%)		32 (40%)	14 (31.1%)
T stage
T1	23 (23%)	45 (19%)	27 (22.5%)	0.35	7 (8.7%)	3 (6.7%)	0.91
T2	36 (36%)	81 (34.2%)	46 (38.3%)		23 (28.8%)	15 (33.3%)
T3	30 (30%)	65 (27.4%)	24 (20%)		30 (37.5%)	15 (33.3%)
T4	11 (11%)	46 (19.4%)	23 (19.2%)		20 (25%)	12 (26.7%)
N stage
N0	13 (13%)	26 (11%)	12 (10%)	0.93	23 (28.7%)	14 (31.1%)	0.99
N1	53 (53%)	132 (55.7%)	73 (60.8%)		32 (40%)	18 (40%)
N2	27 (27%)		29 (24.2%)		19 (23.8%)	10 (22.2%)
N3	7 (7%)	57 (24.1%)22 (9.2%)	6 (5%)		6 (7.5%)	3 (6.7%)
Overall stage (AJCC eighth edition)
I	42 (42%)	98 (41.4%)	62 (51.7%)	0.07	22 (27.5%)	13 (28.9%)	0.97
II	41 (41%)	76 (32%)	30 (25%)		32 (40%)	17 (37.8%)
III	17 (17%)	63 (26.6%)	27 (22.5%)		26 (32.5%)	15 (33.3%)
IV	0 (0%)	0 (0%)	1 (0.8%)		0 (0%)	0 (0%)